Mohamad Mohty, MD, PhD

Mohamad Mohty, MD, PhD, discusses the potential role of BCMA-targeted bispecific antibodies in myeloma.

Mohamad Mohty, MD, PhD, shares the rationale for investigating the real-world efficacy of elranatamab in relapsed/refractory multiple myeloma.

Mohamad Mohty, MD, PhD, discusses the real-world efficacy of elranatamab in patients with relapsed/refractory multiple myeloma.

Mohamad Mohty, MD, PhD, discusses the promise of the phase 2 MagnetisMM-3 trial in patients with relapsed/refractory multiple myeloma, which is investigating elranatamab monotherapy in this patient population.

Mohamad Mohty, MD, PhD, discusses unmet needs in patients with relapsed/refractory multiple myeloma and the rationale for investigating elranatamab monotherapy in this population in the phase 2 MagnetisMM-3 trial.

Mohamad Mohty, MD, PhD, discusses extended follow-up from cohort A of the phase 2 MagnetisMM-3 trial of elranatamab in patients with relapsed/refractory multiple myeloma.